Maze Therapeutics, Inc. · NASDAQ:MAZE

James Tananbaum reported a 5.60% stake in Maze Therapeutics, Inc. (Schedule 13G)

Event Jan 31, 2025 · Filed Feb 7, 2025

James Tananbaum reported a 5.60% stake in Maze Therapeutics, Inc., 2,457,108 shares, as a passive investor on Jan 31, 2025. Filed Feb 7, 2025 (Schedule 13G).

Stake
5.60%
Shares
2,457,108
Intent
Passive
What changed
Crossed above 5%
Filed together
5 holders

The filing in full

HolderStakeShares
Foresite Capital Fund IV, L.P.4.80%2,111,917
Foresite Capital Management IV, LLC4.80%2,111,917
Foresite Capital Fund V, L.P.0.80%345,191
Foresite Capital Management V, LLC0.80%345,191
James Tananbaum5.60%2,457,108

Source

View original at SEC

Related